Published in Clin Infect Dis on January 01, 2003
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Iron metabolism and the innate immune response to infection. Microbes Infect (2011) 1.32
Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr (2008) 1.04
Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. BMC Infect Dis (2011) 1.03
Anaemia in acute HIV-1 subtype C infection. PLoS One (2008) 0.96
Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD. AIDS Res Treat (2012) 0.95
Prevalence and correlates of cytopenias in HIV-infected adults initiating highly active antiretroviral therapy in Uganda. BMC Infect Dis (2014) 0.91
Inverse relationship of serum hepcidin levels with CD4 cell counts in HIV-infected patients selected from an Indonesian prospective cohort study. PLoS One (2013) 0.89
Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondar University Hospital, Northwest Ethiopia. BMC Hematol (2013) 0.88
HIV symptom burden and anemia among HIV-positive individuals: cross-sectional results of a community-based positive living with HIV (POLH) study in Nepal. PLoS One (2014) 0.83
Anemia in a cohort of HIV-infected Hispanics: prevalence, associated factors and impact on one-year mortality. BMC Res Notes (2014) 0.82
Higher serum iron is associated with increased oxidant stress in HIV-infected men. J Acquir Immune Defic Syndr (2013) 0.78
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events. J Acquir Immune Defic Syndr (2016) 0.76
An Evaluation of Alternative Markers to Guide Initiation of Anti-retroviral Therapy in HIV-Infected Children in Settings where CD4 Assays are not Available. J Trop Pediatr (2015) 0.75
Anaemia in pregnancy is associated with advanced HIV disease. PLoS One (2014) 0.75
Women, Aging, and HIV: Clinical Issues and Management Strategies. J Nurse Pract (2014) 0.75
Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study. Am J Trop Med Hyg (2015) 0.75
Iron overload down-regulates the expression of the HIV-1 Rev cofactor eIF5A in infected T lymphocytes. Proteome Sci (2017) 0.75
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis (2002) 2.87
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis (2008) 2.72
Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis (2007) 2.51
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS (2010) 2.04
Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS (2009) 1.90
Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis (2009) 1.86
Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther (2008) 1.83
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS (2009) 1.81
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS (2011) 1.68
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology (2011) 1.59
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer (2010) 1.53
Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS (2009) 1.42
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study). PLoS One (2013) 1.36
Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis (2006) 1.28
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr (2006) 1.27
Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS (2008) 1.25
The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS (2008) 1.18
Medical and societal consequences of late presentation. Antivir Ther (2010) 1.17
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS (2012) 1.16
HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. Blood (2011) 1.13
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS (2008) 1.11
Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis (2004) 1.09
Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS (2011) 1.06
Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther (2009) 1.04
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr (2009) 1.04
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr (2009) 1.04
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS (2014) 1.03
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS (2008) 0.99
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials (2011) 0.98
HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther (2006) 0.96
Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One (2012) 0.95
Associations between immune depression and cardiovascular events in HIV infection. AIDS (2013) 0.94
Biomarkers of impaired renal function. Curr Opin HIV AIDS (2010) 0.93
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis (2002) 0.93
Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retroviruses (2007) 0.92
Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS (2010) 0.92
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS (2011) 0.91
Highly active antiretroviral therapy and cervical intraepithelial neoplasia. AIDS (2002) 0.91
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol (2013) 0.90
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr (2008) 0.89
HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med (2004) 0.88
Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother (2010) 0.88
The impact of antiretroviral therapy on AIDS and survival. J HIV Ther (2006) 0.88
Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS (2015) 0.85
Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons. Curr Opin HIV AIDS (2014) 0.85
Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One (2013) 0.85
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J Infect Dis (2012) 0.84
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS (2013) 0.84
The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. Cent Eur J Public Health (2008) 0.84
Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. Eur Respir J (2013) 0.83
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther (2009) 0.83
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther (2011) 0.83
Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. AIDS (2016) 0.82
Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis (2012) 0.82
HIV therapies and the kidney: some good, some not so good? Curr HIV/AIDS Rep (2012) 0.81
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr (2012) 0.81
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J Infect Dis (2007) 0.80
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC Infect Dis (2014) 0.79
Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr (2010) 0.79
Incidence of abacavir hypersensitivity reactions in euroSIDA. Antivir Ther (2008) 0.78
Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scand J Infect Dis (2008) 0.77
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol (2014) 0.77
The cardiovascular risk management for people living with HIV in Europe: how well are we doing? AIDS (2016) 0.77
[Decline in AIDS and death rates in the EuroSIDA study. An observational study]. Ugeskr Laeger (2004) 0.76
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS (2015) 0.76
Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS (2016) 0.75
Use of risk equations for predicting disease progression in HIV infection. Clin Infect Dis (2009) 0.75
Thrombocytopenia and cancer risk during HIV infection. AIDS (2015) 0.75
Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. AIDS (2008) 0.75
Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. Medicine (Baltimore) (2016) 0.75
Analysis of the incidence and mortality of vulval cancer in women in South East England 1960-1999. Arch Gynecol Obstet (2008) 0.75
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. AIDS (2016) 0.75
Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. AIDS (2017) 0.75
Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J Acquir Immune Defic Syndr (2002) 0.75
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals. AIDS (2017) 0.75
Associations between HIV-RNA-based indicators and virological and clinical outcomes. AIDS (2016) 0.75